Newsroom | 4296 results

DUBLIN--(BUSINESS WIRE)--The "Exosome Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2020-2030" has been added to ResearchAndMarkets.com's offering. The Global Exosome Therapeutics Market, valued at USD 32.63 Million in 2024, is projected to experience a CAGR of 41.56% to reach USD 262.58 Million by 2030. The market's expansion is fundamentally supported by an escalating understanding of exosome biology, the increasing prevalence of chronic and age-relat...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mission Bio, Inc., a leader in single-cell multi-omic solutions for precision medicine, announced that its Tapestri Platform and custom assay development supported initial exploratory biomarker analysis data presented by Incyte at the ASH 2025 conference in Orlando, Florida, in December. The data demonstrate Tapestri® Platform’s ability to accelerate the understanding of Myeloproliferative Neoplasms (MPNs) disease biology at the single-cell level. M...

SEATTLE--(BUSINESS WIRE)--Curi Bio is thrilled to announce the close of a $10 Million Series B financing round, led by DreamCIS....

BOSTON--(BUSINESS WIRE)--Ensoma, an in vivo cellular engineering company with a mission to advance the future of medicine through one-time therapies, today announced that the first patient has been dosed in the company’s Phase 1/2 clinical trial of EN-374. EN-374 is an in vivo hematopoietic stem cell (HSC)-directed gene insertion therapy for the treatment of X-linked chronic granulomatous disease (X-CGD), a rare and severe genetic disorder. “Dosing our first patient in this Phase 1/2 trial is a...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on November 28, 2025. One individual was hired by Adicet in November 2025 and granted new hire non-qualified stock options to purchase 20,600 shares of Adicet’s common stock with an exercise price of $0.65 per share, the closing price of...

DUBLIN--(BUSINESS WIRE)--The "Graft Versus Host Disease (GvHD) Treatment - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for Graft Versus Host Disease (GvHD) Treatment was valued at US$2.9 Billion in 2024 and is projected to reach US$4.5 Billion by 2030, growing at a CAGR of 7.3% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisio...

IRVINE, Calif.--(BUSINESS WIRE)--Immunis, Inc., a clinical-stage biotech pioneering multi-active stem cell-derived biologics for age and disease-related immune dysregulation, today announced it has been named one of the Top 50 Healthcare Technology Companies of 2025 by The Healthcare Technology Report, recognizing notable advances in next-generation therapeutics, care delivery and clinical insights. The recognition follows the company’s recent publication in Obesity showing body fat loss and in...

SAN FRANCISCO--(BUSINESS WIRE)--Susannah Cantrell, PhD, has joined Ossium Health's leadership team as Chief Commercial Officer (CCO)....

DUBLIN, Ireland--(BUSINESS WIRE)--Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025...

DUBLIN--(BUSINESS WIRE)--The "Cell and Gene Therapy Business Outlook" report has been added to ResearchAndMarkets.com's offering. The Twice-Monthly Publication Cell and Gene Therapy Business Outlook will offer the following: Market Sizing and Forecasting of CAGT Markets: Each issue sizes up the market opportunity and projects the future revenues for a given therapeutic segment. Keeping an Eye on Financing: With billions of investment dollars announced each year, Cell and Gene Therapy Business O...